期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

治疗SLE靶向新型制剂的回顾与进展 被引量：1

Review and Progress of Target Drugs in the Treatment of Systemic Lupus Erythematous
原文传递
导出
摘要 系统性红斑狼疮(systemic lupus erythematous,SLE)的发病机制复杂,临床表现多样化。目前SLE的治疗主要以激素和免疫抑制剂的联用为主,近年来,细胞乃至分子生物学的发展使SLE的发病机制得到新的阐述,从而涌现出了一大批通过调节T、B细胞治疗SLE的靶向药生物制剂。本文对此类药物的研究进展进行了一个综合性的论述,为SLE药物的临床应用提供阶段性的参考。 As the disease with complex symptom and poorly understanding pathology, treatment of systemic lupus erythematous （SLE） is still mainly based on “traditional” drugs, corticosteroids and immunosuppressive. However the mechanism of SLE has been promoted to several levels and provided a brand new clue of target treatment. The research and exploration on biological agents has been put efforts, thus a large number of biological drugs emerged due to regulate the activation of T and B cell through many aspects of immune reaction. The article will present the drugs of each classification and apply an temporary reference for clinical medical therapy guidance.
作者 李晶佳 云彩鳞 刘小雷
机构地区 内蒙古医科大学药学院
出处 《中国现代应用药学》 CAS CSCD 2013年第3期333-337,共5页 Chinese Journal of Modern Applied Pharmacy
关键词 系统性红斑狼疮 药物治疗 靶向药物 SLE medication associated mechanism
分类号 R943.42 [医药卫生—药剂学]
  • 相关文献

参考文献39

  • 1CAROLlNE C, CHARLES K L, DAVID I. Systemic lupus erythematosus [J]. Medicine, 20 I 0, 38(2): 73-80.
  • 2SHU M F, MESH S D, FELl CIA G. Pathogenesis of systemic lupus erythematosus revisited 20 11: End organ resistance to damage, autoantibody initiation and diversification, and HLA-DR [J].J Autoimmunity, 2011, 37(2): 104-112.
  • 3LIN, H L, YENJ H, CHOU S S, et al. Estradiol up regulates calcine urine expression via over expression of estrogen receptor alpha gene in systemic lupus erythematosus [J]. KaohsiungJ Med Sci, 2011, 27(4): 125-131.
  • 4MARIANA P, SIMONE A. The role of tumor necrosis factor-alpha (TNF-a) in the pathogenesis of systemic lupus erythematosus [J]. Cytokine, 2011, 56(3): 537-543.
  • 5SALLOUM R, NIEWOLD T B. Interferon regulatory factors in human lupus pathogenesis [J]. Transl Res, 2011, 157(6): 326-331.
  • 6李若洁,叶冬青.系统性红斑狼疮的全基因组关联研究进展[J].中华疾病控制杂志,2011,15(7):614-618. 被引量：20
  • 7周志轩,赖建铭,扬丽萍,黄小兰,吴凤岐.利妥昔单抗治疗儿童系统性红斑狼疮12例临床研究[J].中国实用儿科杂志,2010,25(8):611-613. 被引量：14
  • 8ROBERT G L. Systemic lupus Erythematosus [M]. 5th Ed. US: Academic Press, 2010: 1045-1060.
  • 9BLUMENFELD Z, MISCHARI 0, SCHULTZ N, et al. Gonadotropin releasing hormone agonists may minimize cyclophosphamide associated gonadotoxicity in SLE and autoimmune diseases [J]. Semin Arthritis Rheum, 2011, 41(3): 346-352.
  • 10RADOMIR N, DIJANAJ, STEVAN P, et al. Cyclosporine versus azathioprine therapy in high-risk idiopathic membranous nephropathy patients: A 3-year prospective study [J]. Biomed Pharm, 2011 65(2): 105-110.

二级参考文献117

共引文献53

同被引文献29

  • 1Tokunaga M, Saito K, Kawabata D, et al. Efficacy of rituximab (anti- CD20 )for refractory systemic lupus erythematosus involving the central nervous system [J]. Ann Rheum Dis, 2007,66 ( 4 ) :470 - 475. DOI : 10. 1136/ard. 2006. 057885.
  • 2Merrill JT, Neuweh CM, Wallace DJ, et al. Efficacy and safety of ritux- imab in moderately-to-severely active systemic lupus erythematosus:the randomized, double-blind, phase 1I//Ill systemic lupus erythematosus evaluation of rituximab trial[J]. Arthritis Rheum, 2010,62 (1) :222 - 233. DOI:10. 1002/art. 27233.
  • 3Rovin BH,Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis:the Lupus Nephritis As- sessment with Rituximab study [J]. Arthritis Rheum, 2012,64 ( 4 ) : 1215 - 1226. DOI:10. 1002/art. 34359.
  • 4Matsumiya S, Yamaguchi Y, Saito J, et al. Structural comparison of fuco- sylated and nonfueosylated Fc fragments of human immunoglobulin G1 [J]. J Mol Bio1,2007,368 ( 3 ) :767 - 790. DOI : 10. 1016/j. jmb. 2011. 03.031.
  • 5Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double- blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus [J]. Arthritis Rheum,2009,61 (9) : 1 !68 - 1178. DOI : 10. 1002/art. 24699.
  • 6Navarra SV, Guzm6n RM, Gallacher AE, et al. Efficacy and safety of be- limumab in patients with active systemic lupus erythematosus : a rando- mised, placebo-controlled, phase 3 trial[J]. Lancet, 2011,377 ( 9767 ) : 721 -731. DOI:10.1016/S0140-6736( 10)61354-2.
  • 7Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-con- trolled study of belimumab, a monoclonal antibody that inhibits B lym- phocyte stimulator, in patients with systemic lupus erythematosus [J]. Arthritis Rheum, 2011,63 ( 12 ) : 3918 - 3930. DOI: 10. 1002/art. 30613.
  • 8Hsu H, Khare SD, Lee F, et al. A novel modality of BAFF-specific inhi- bitor AMG623 peptibody reduces B-cell number and improves outcomes in murine models of autoimmune disease [J]. Clin Exp Rheumatol, 2012,30(2) :197 -201.
  • 9Furie RA, Leon G,Thomas M, et al. A phase 2, randomised, placebo- controlled clinical trial of blisibimod, an inhibitor of B cell activating factor,in patients with moderate-to-severe systemic lupus erythemato- sus, the PEARL-SC study [J]. Ann Rheum Dis,2015,74 (9) : 1667 - 1675. DOI : 10.1136/annrheumdis-2013-205144.
  • 10Cardiel MH,Tumlin JA, Furie RA, et al. Abetimus Sodium for renal flare in systemic lupus erythematosus: results of a randomized, con- trolled phase III trial [J]. Arthritis Rheum, 2008,58 ( 8 ) : 2470 - 2480. DOI: 10. 1002/art. 23673.

引证文献1

二级引证文献5

中国现代应用药学
2013年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部